Fig 2: Depletion of NEK2 by siRNA inhibits the growth of LNCaP subcutaneous xenograft growth in nude mice. a & b Representative images of LNCaP xenografts. c Tumor growth curves of LNCaP xenografts. d & e Immunostaining of NEK2 in LNCaP xenografts. The figure magnification is × 200 and × 400, respectively. f Statistical analysis of the NEK2 positive cells in the immunostaining

Fig 3: Immunohistochemical staining for NEK2 expression in PCa and adjacent non-cancerous tissues (original magnification × 50). a Benign prostate tissue. b PCa with a Gleason score <8. c PCa with a Gleason score ≥8. d statistical analyses showing higher immunoreactivity scores in cancerous tissues than in adjacent non-cancerous tissues. (IRS: Ca = 4.25 ± 1.36 vs Benign = 2.93 ± 1.51, P =0.03). a, b, and c were from TMA sample NO. A5, J8, and H8, respectively

Fig 4: High NEK2 expression is linked to poor prognosis in PCa patients. a Kaplan–Meier analyses of the biochemical recurrence-free time of PCa patients with high NEK2 expression levels was shorter than those with low NEK2 expression levels (P = 0.037). b The overall survival time of PCa patients was not correlated to NEK2 expression levels (P = 0.762)